- Home
- RGP vs ELDN Comparison
RGP vs ELDN Comparison
Compare RGP & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGP
- ELDN
- Stock Information
- Founded
- RGP 1996
- ELDN 2004
- Country
- RGP United States
- ELDN United States
- Employees
- RGP N/A
- ELDN N/A
- Industry
- RGP Business Services
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- RGP Consumer Discretionary
- ELDN Health Care
- Exchange
- RGP Nasdaq
- ELDN Nasdaq
- Market Cap
- RGP 155.0M
- ELDN 164.1M
- IPO Year
- RGP 2006
- ELDN N/A
- Fundamental
- Price
- RGP $4.42
- ELDN $3.34
- Analyst Decision
- RGP Buy
- ELDN Strong Buy
- Analyst Count
- RGP 2
- ELDN 2
- Target Price
- RGP $6.00
- ELDN $12.50
- AVG Volume (30 Days)
- RGP 533.7K
- ELDN 1.5M
- Earning Date
- RGP 10-08-2025
- ELDN 11-11-2025
- Dividend Yield
- RGP 6.32%
- ELDN N/A
- EPS Growth
- RGP N/A
- ELDN N/A
- EPS
- RGP N/A
- ELDN 0.21
- Revenue
- RGP $534,625,000.00
- ELDN N/A
- Revenue This Year
- RGP N/A
- ELDN N/A
- Revenue Next Year
- RGP $12.36
- ELDN N/A
- P/E Ratio
- RGP N/A
- ELDN $15.56
- Revenue Growth
- RGP N/A
- ELDN N/A
- 52 Week Low
- RGP $4.23
- ELDN $2.32
- 52 Week High
- RGP $9.96
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- RGP 41.20
- ELDN 61.67
- Support Level
- RGP $4.27
- ELDN $3.23
- Resistance Level
- RGP $4.49
- ELDN $3.76
- Average True Range (ATR)
- RGP 0.26
- ELDN 0.26
- MACD
- RGP -0.02
- ELDN 0.06
- Stochastic Oscillator
- RGP 21.57
- ELDN 58.07
About RGP Resources Connection Inc.
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.